Prevalence and affinity/avidity assessment of pre-existing NABs against AAV2, 5 and 8 analyzed in the serum of 300 healthy donors

被引：0
|
作者：
Majowicz, A. [1 ]
van Waes, F. [1 ]
Timmer, N. [1 ]
van Deventer, S. J. [1 ]
Ferreira, V. [1 ]
机构：
[1] UniQure Biopharma BV, Amsterdam, Netherlands
来源：
HUMAN GENE THERAPY | 2019年 / 30卷 / 11期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P336
引用
收藏
页码：A116 / A116
页数：1
相关论文
共 18 条
  • [1] PREVALENCE AND AFFINITY/AVIDITY ASSESSMENT OF PRE-EXISTING NABS AGAINST AAV1, 2, 5 AND 8 ANALYZED IN THE SERUM OF 300 HEALTHY DONORS
    Majowicz, A.
    van Waes, F.
    Timmer, N.
    van Deventer, S. J.
    Ferreira, V.
    [J]. HAEMOPHILIA, 2020, 26 : 53 - 53
  • [2] Prevalence and Avidity Assessment of Pre-Existing Neutralizing Antibodies (NABs) Against Adeno-Associated Virus (AAV) Vector Serotypes 2, 5 and 8 Analyzed in the Serum of 300 Healthy Donors
    Majowicz, Anna
    van Waes, Floris
    Timmer, Nikki
    van Deventer, Sander J.
    Ferreira, Valerie
    [J]. MOLECULAR THERAPY, 2020, 28 (04) : 517 - 518
  • [3] Impact of Pre-Existing Neutralizing Antibodies (NAbs) on Expression of a SIV Antibody Following Intramuscular (IM) Administration of AAV2/8
    Greig, Jenny A.
    Grant, Rebecca L.
    Bote, Erin
    Peng, Hui
    Medina-Jaszek, C. Angelica
    Ahonkhai, Omua
    Bell, Peter
    Calcedo, Roberto
    Tretiakova, Anna
    Wilson, James M.
    [J]. MOLECULAR THERAPY, 2012, 20 : S100 - S101
  • [4] Pre-Existing Neutralizing Antibodies to AAV2 and AAV5 in the Serum and Synovial Fluid of 20 Horses
    Ortved, Kyla F.
    Calcedo, Roberto
    Nixon, Alan J.
    [J]. MOLECULAR THERAPY, 2012, 20 : S48 - S48
  • [5] Prevalence of pre-existing immunity to AAV8 and other AAV serotypes in healthy individuals
    Kruzik, A.
    Fetahagic, D.
    Hartlieb, B.
    Horling, F. M.
    Scheiflinger, F.
    Reipert, B. M.
    de la Rosa, M.
    [J]. HUMAN GENE THERAPY, 2017, 28 (12) : A21 - A22
  • [6] Seroprevalence of Pre-Existing Nabs Against AAV1, 2, 5, 6 and 8 in South African Hemophilia B Patient Population
    Majowicz, Anna
    Ncete, Nolukholo
    van Waes, Floris
    Timmer, Nikki
    van Deventer, Sander J.
    Mahlangu, Johnny N.
    Ferreira, Valerie
    [J]. BLOOD, 2019, 134
  • [7] SEROPREVALENCE OF PRE-EXISTING NABS AGAINST AAV1, 2, 5, 6 AND 8 IN SOUTH AFRICAN HEMOPHILIA B PATIENT POPULATION
    Mahlangu, J. N.
    Majowicz, A.
    Ncete, N.
    van Waes, F.
    Timmer, N.
    van Deventer, S. J.
    Ferreira, V.
    [J]. HAEMOPHILIA, 2020, 26 : 88 - 88
  • [8] Characterization of Human Pre-Existing Cellular Immunity against Aav 2, 4, 5, 8 and 9 Serotypes
    Xicluna, Rebecca
    Devaux, Marie
    Couzinie, Celia
    Jaulin, Nicolas
    Vandamme, Celine
    Adjali, Oumeya
    [J]. MOLECULAR THERAPY, 2018, 26 (05) : 109 - 109
  • [9] Pre-Existing Anti-Adeno-Associated Virus (AAV) Serotype 5 Neutralizing Antibodies (NABs) Titers in Minipig Serum Do Not Reflect Levels of Anti-AAV5 NABs Titers in Their Cerebrospinal Fluid (CSF)
    Majowicz, Anna
    Valles, Astrid
    van Waes, Floris
    Bohuslavova, Bozena
    Ellederova, Zdenka
    Motlik, Jan
    Higgins, Joseph
    van Deventer, Sander
    Konstantinova, Pavlina
    Ferreira, Valerie
    [J]. MOLECULAR THERAPY, 2019, 27 (04) : 140 - 140
  • [10] Presence of Pre-Existing Anti-Adeno-Associated Virus (AAV) Serotype 5 Neutralizing Antibodies (NABs) in Serum of Huntington Disease (HD) Patients Was Not Associated with Detectable Anti-AAV5 Nabs in Cerebrospinal Fluid (CSF)
    Majowicz, Anna
    van Waes, Floris
    Valles, Astrid
    van Deventer, Sander
    Gilling, Mette
    Ehrhardt, Anka
    Konstantinova, Pavlina
    Sier-Ferreira, Valerie
    [J]. MOLECULAR THERAPY, 2021, 29 (04) : 357 - 357
12